Dexcom Inc

Dexcom’s new G7 CGM delivers proven safety, better time‑in‑range, and a 10‑day sensor, keeping its market lead amid share‑price swings and a big institutional sale.

Institutional investors back Dexcom (DXCM) as its CGM tech, market lead and expanding global reach drive confidence in a resilient, growth‑oriented diabetes‑care platform.

Dexcom’s new CEO, Jake Leach, is steering a shift toward AI‑powered glucose monitoring, low‑cost sensors, and global expansion to boost CGM market share and profitability.

Dexcom’s CGM tech faces legal scrutiny and price‑target cuts; learn how litigation, margin pressure, and market gaps shape its future.

Dexcom faces a securities lawsuit, mixed analyst views, and margin cuts that temper strong earnings, leaving investors in a cautious consolidation phase.

Dexcom Inc.’s stock price has experienced notable fluctuations due to a mix of market volatility, sector-specific challenges, and macro-economic factors, but the company’s strong earnings potential and growing demand for continuous glucose monitorin…

Dexcom Inc.’s stock price has declined by 5% following analyst downgrades, but the company’s long-term prospects remain positive due to its innovative pipeline and commitment to transforming diabetes care.

Dexcom Inc., a leading continuous glucose monitoring (CGM) technology company, is facing a multi-faceted crisis due to reliability concerns, short-seller pressure, and a tightening competitive landscape, which may impact its financial fundamentals, …

Dexcom Inc’s stock price declined by 6% after the company released its Q2 earnings, despite financial experts maintaining a strong buy rating due to its high growth potential.

Dexcom Inc.’s stock price has declined due to broader market volatility, falling below its 52-week high and sparking concerns about the company’s future prospects.